Hisun's Subsidiary Secures US Self-GRAS Approval for Glucosamine Hydrochloride

Stock News09-11

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has announced that its wholly-owned subsidiary, Zhejiang Yunsheng Synthetic Biology Co., Ltd., has successfully passed the US Self-GRAS certification for its Glucosamine Hydrochloride product. This milestone was achieved following a comprehensive scientific evaluation conducted in accordance with the US FDA GRAS criteria, which received unanimous approval from the expert panel convened for the review.

Glucosamine Hydrochloride is recognized as a high-value food-grade raw material with extensive applications in food formulation and nutritional ingredient sectors. Within the US market, this product can now be utilized as a food ingredient under the proposed intended use conditions, spanning various food categories including specific food products and meal replacement items. This certification enables the product's application across these diverse food segments, broadening its commercial potential.

The attainment of the Self-GRAS certification signifies that the product is now eligible for sale and use as a safe dietary ingredient in the US market, as well as in other international markets that recognize the US GRAS certification standard. This achievement is expected to further enrich the company's profit structure and lay a critical foundation for the global expansion of its dietary product business, positioning the company strategically for enhanced international market penetration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment